ClinicalTrials.gg
CompletedNCT03831880Updated Oct 14, 2021Results posted

Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD

A Phase 3 interventional study of Genotropin and somatrogon in Growth Hormone Deficiency, sponsored by Pfizer. Completed at 32 sites in 5 countries. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-10-14.

Sponsored by Pfizer · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
3 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.

Enrollment
24th of 60
87 · median 66
Started
2019
with 1 other
Phase 3
23 of 60
2 open now
Registered
56th of 60
by date
Lead sponsor
5 of 60
Pfizer

Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 24th largest by enrollment, is one of 2 that started in 2019, is one of 23 in phase 3, and was the 56th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 3 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, or all of them as a file.
02

Study summary

This is an open label randomized 24 week crossover trial assessing the treatment burden of a weekly growth hormone injection regimen (somatrogon) compared to a daily growth hormone injection regimen (Genotropin). Approximately 90 children with growth hormone deficiency who have been stable on treatment with daily Genotropin will be enrolled.

Read the detailed description

Subjects will be randomized to one of two sequences, either 12 weeks of continued treatment with daily Genotropin followed by 12 weeks of treatment with weekly somatrogon, or 12 weeks of treatment with weekly somatrogon followed by 12 weeks of treatment with daily Genotropin. Subjects will have study visits at Baseline, Weeks 6, 12, 18, and 24. Subjects will also be followed up by phone 8 to 12 days after each treatment period begins (Week 1 and Week 13). Subjects and caregivers (as a Dyad) will complete questionnaires assessing treatment burden at baseline and at the end of each 12 week treatment period. All subjects/caregivers will receive a follow up phone call at Week 28.

03

Conditions studied

  • Growth Hormone Deficiency

Browse trials for

04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Children aged 3 years old and \<18 years with either isolated GHD, or GH insufficiency.
  2. Currently on treatment with either Genotropin Pen®, Genotropin GoQuick Pen®, HumatroPen® (United States of America [USA] only), or Omnitrope® Pen (USA only) ≥3 months and have been compliant on a stable dose (±10%) for at least 3 months prior to screening.
  3. IGF I SDS \< 2.
  4. Subjects on hormonal replacement therapy for other hypothalamic pituitary axis (HPA) hormonal deficiencies and/or diabetes insipidus must be on an optimized and stable treatment regimen, as determined by the Investigator, for at least 3 months prior to screening.

Exclusion criteria

Exclusion Criteria

  1. History of leukemia, lymphoma, sarcoma or any other cancer.
  2. History of radiation therapy or chemotherapy.
  3. Children with psychosocial dwarfism.
  4. Children born small for gestational age (SGA) - birth weight and/or birth length \< 2 SDS for gestational age.
  5. Other causes of short stature such as uncontrolled primary hypothyroidism and rickets.
  6. Chromosomal abnormalities including Turner's syndrome, Laron syndrome, Noonan syndrome, Prader Willi syndrome, Russell Silver syndrome, short stature homeobox (SHOX) mutations/deletions or skeletal dysplasias.
  7. Treatment with regularly scheduled daily or weekly injectable medications other than Genotropin® Pen, Genotropin GoQuick®, HumatroPen® (USA only), or Omnitrope® Pen (USA only).
  8. Diabetes Mellitus.
  9. Current treatment with Genotropin MiniQuick.
  10. History of any exposure to a long acting hGH preparation.
  11. Known or suspected (HIV) positive patient, or patient with advanced diseases such as acquired immunodeficiency syndrome (AIDS) or tuberculosis.
  12. Drug, substance, or alcohol abuse.
  13. Known to the components of the medication.
  14. Pregnant female subjects; breastfeeding female subjects; fertile male subjects and female subjects of who are unwilling or unable to use a highly effective method of as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of product.
  15. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  16. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
  17. Participation in other studies involving investigational drug(s) within 30 days prior to study entry and/or during study participation.
  18. Patient and/or the parent/legal guardian are likely to be non-compliant with respect to study conduct.
  19. Subject and/or the parent/legal guardian are unable to understand written and/or verbal instructions on the proper use of growth hormone injection devices.
  20. Children with closed epiphyses (this determination can be based on available existing clinical data).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
87 participants (actual)

Study arms

  • Other
    Daily to Weekly

    Genotropin to somatrogon

    Drug: Genotropin · Drug: somatrogon

  • Other
    Weekly to Daily

    somatrogon to Genotropin

    Drug: Genotropin · Drug: somatrogon

Interventions

  • Genotropin (dose \[mg\] at time of enrollment) given subcutaneously once daily

  • 0.66 mg/kg/week given subcutaneously once weekly

06

What researchers measure

Primary outcomes

  1. Total Score Related to Overall Life Interference Assessed at Baseline, Using Dyad Clinical Outcomes Assessment 1 (DCOA 1) Questionnaire

    Participants were assessed for their treatment burden using DCOA 1 questionnaire completed by participant/caregiver dyads. The participant life interference questionnaire component of the DCOA 1 had 7 questions (life interference \[5 questions\]: a measure of life interference \[daily activities/social activities/leisure/night away from home/travel\]; life interference-changes to life routine \[1 question\]: a measure of how often changes are made to life routine; and life interference-bother of growth hormone \[GH\] injections \[1 question\]: a measure of how often the growth hormone injections cause bother) and all questions used a 5-point scale: 1= never, 2= rarely, 3= sometimes, 4= often, 5= always. The overall life interference total score was sum of all 7 questions, scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant less life interference (better outcome).

    Time frame: Baseline

  2. Total Score Related to Overall Life Interference Assessed at Week 12, Using DCOA 1 Questionnaire

    Participants were assessed for their treatment burden using DCOA 1 questionnaire completed by participant/caregiver dyads. The participant life interference questionnaire component of the DCOA 1 had 7 questions (life interference \[5 questions\]: a measure of life interference \[daily activities/social activities/leisure/night away from home/travel\]; life interference-changes to life routine \[1 question\]: a measure of how often changes are made to life routine; and life interference-bother of growth hormone \[GH\] injections \[1 question\]: a measure of how often the growth hormone injections cause bother) and all questions used a 5-point scale: 1= never, 2= rarely, 3= sometimes, 4= often, 5= always. The overall life interference total score was sum of all 7 questions, scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant less life interference (better outcome).

    Time frame: Week 12

  3. Total Score Related to Overall Life Interference Assessed at Week 24, Using DCOA 1 Questionnaire

    Participants were assessed for their treatment burden using DCOA 1 questionnaire completed by participant/caregiver dyads. The participant life interference questionnaire component of the DCOA 1 had 7 questions (life interference \[5 questions\]: a measure of life interference \[daily activities/social activities/leisure/night away from home/travel\]; life interference-changes to life routine \[1 question\]: a measure of how often changes are made to life routine; and life interference-bother of growth hormone \[GH\] injections \[1 question\]: a measure of how often the growth hormone injections cause bother) and all questions used a 5-point scale: 1= never, 2= rarely, 3= sometimes, 4= often, 5= always. The overall life interference total score was sum of all 7 questions, scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant less life interference (better outcome).

    Time frame: Week 24

  4. Total Score Related to Overall Life Interference by Treatment in Overall Study, Using DCOA 1 Questionnaire

    Participants were assessed for their treatment burden using DCOA 1 questionnaire completed by participant/caregiver dyads. The participant life interference questionnaire component of the DCOA 1 had 7 questions (life interference \[5 questions\]: a measure of life interference \[daily activities/social activities/leisure/night away from home/travel\]; life interference-changes to life routine \[1 question\]: a measure of how often changes are made to life routine; and life interference-bother of growth hormone \[GH\] injections \[1 question\]: a measure of how often the growth hormone injections cause bother) and all questions used a 5-point scale: 1= never, 2= rarely, 3= sometimes, 4= often, 5= always. The overall life interference total score was sum of all 7 questions, scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant less life interference (better outcome).

    Time frame: Baseline up to Week 24

Secondary outcomes

  1. Total Score Related to Pen Ease of Use Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire

    Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked 5 questions from Section I of the Injection Pen Assessment Questionnaire (IPAQ) patient-reported outcome (PRO) tool related to pen ease of use and used a 5-point scale: 1= very easy, 2= somewhat easy, 3= neither easy nor difficult, 4= somewhat difficult, 5= very difficult. The total score related to pen ease of use was sum of all 5 questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.

    Time frame: Baseline, Week 12, Week 24

  2. Total Score Related to Pen Ease of Use by Treatment in Overall Study, Using DCOA 1 Questionnaire

    Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked 5 questions from Section I of the IPAQ PRO tool related to pen ease of use and used a 5-point scale: 1= very easy, 2= somewhat easy, 3= neither easy nor difficult, 4= somewhat difficult, 5= very difficult. The total score related to pen ease of use was sum of all 5 questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.

    Time frame: Baseline up to Week 24

  3. Total Score Related to Ease of the Injection Schedule Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire

    Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to ease of injection schedule and used a 5-point scale: 1= very easy, 2= somewhat easy, 3= neither easy nor difficult, 4= somewhat difficult, 5= very difficult. The total score related to ease of the injection schedule ranged from 1 to 5; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.

    Time frame: Baseline, Week 12, Week 24

  4. Total Score Related to Ease of the Injection Schedule by Treatment in Overall Study, Using DCOA 1 Questionnaire

    Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to ease of injection schedule and used a 5-point scale: 1= very easy, 2= somewhat easy, 3= neither easy nor difficult, 4= somewhat difficult, 5= very difficult. The total score related to ease of the injection schedule ranged from 1 to 5; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.

    Time frame: Baseline up to Week 24

  5. Total Score Related to Convenience of the Injection Schedule Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire

    Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to ease of injection schedule and used a 7-point scale: 1=extremely convenient to 7=extremely inconvenient. The total score related to convenience of injection schedule ranged from 1 to 7; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.

    Time frame: Baseline, Week 12, Week 24

  6. Total Score Related to Convenience of the Injection Schedule by Treatment in Overall Study, Using DCOA 1 Questionnaire

    Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to ease of injection schedule and used a 7-point scale: 1=extremely convenient to 7=extremely inconvenient. The total score related to convenience of injection schedule ranged from 1 to 7; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.

    Time frame: Baseline up to Week 24

  7. Total Score Related to Satisfaction With Overall Treatment Experience Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire

    Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to participant satisfaction with treatment and used a 5-point scale: 1=very satisfied to 5=very dissatisfied. The total score related to satisfaction with overall treatment ranged from 1 to 5; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.

    Time frame: Baseline, Week 12, Week 24

  8. Total Score Related to Satisfaction With Overall Treatment Experience by Treatment in Overall Study, Using DCOA 1 Questionnaire

    Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to participant satisfaction with treatment and used a 5-point scale: 1=very satisfied to 5=very dissatisfied. The total score related to satisfaction with overall treatment ranged from 1 to 5; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.

    Time frame: Baseline up to Week 24

  9. Total Scores Related to Willingness to Continue Injection Schedule Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire

    Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to participant willingness to continue treatment and used a 5-point scale: 1=extremely willing to 5=not at all willing. The total score related to willingness to continue injection schedule ranged from 1 to 5; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.

    Time frame: Baseline, Week 12, Week 24

  10. Total Scores Related to Willingness to Continue Injection Schedule by Treatment in Overall Study, Using DCOA 1 Questionnaire

    Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to participant willingness to continue treatment and used a 5-point scale: 1=extremely willing to 5=not at all willing. The total score related to willingness to continue injection schedule ranged from 1 to 5; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.

    Time frame: Baseline up to Week 24

  11. Total Scores Related to Injection Signs and Symptoms for Participants Aged 8 Years and Above Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire

    Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participants (8-17 years old). Participants were asked 4 questions from Section I of the IPAQ PRO tool related to participant's injection signs and symptoms and used a 11-point scale: 0=no pain to 10=worst possible pain; 0=no stinging to 10=worst possible stinging; 0=no bruising to 10=worst possible bruising; and 0=no bleeding to 10=worst possible bleeding, respectively. The total score was sum of all questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for injection signs and symptoms meant a better outcome.

    Time frame: Baseline, Week 12, Week 24

  12. Total Scores Related to Injection Signs and Symptoms for Participants Aged 8 Years and Above by Treatment in Overall Study, Using DCOA 1 Questionnaire

    Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participants (8-17 years old). Participants were asked 4 questions from Section I of the IPAQ PRO tool related to participant's injection signs and symptoms and used a 11-point scale: 0=no pain to 10=worst possible pain; 0=no stinging to 10=worst possible stinging; 0=no bruising to 10=worst possible bruising; and 0=no bleeding to 10=worst possible bleeding, respectively. The total score was sum of all questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for injection signs and symptoms meant a better outcome.

    Time frame: Baseline up to Week 24

  13. Total Scores Related to Assessment of Signs, Completed by Caregiver for Children Aged <8 Years Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire

    Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by caregiver for children under 8 years. Participants were asked 2 questions from Section I of the IPAQ PRO tool related to participant's assessment of signs and used a 11-point scale: 0=no bruising to 10=worst possible bruising and 0=no bleeding to 10=worst possible bleeding, respectively. The total score was sum of all questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for assessment of signs meant a better outcome.

    Time frame: Baseline, Week 12, Week 24

  14. Total Scores Related to Assessment of Signs, Completed by Caregiver for Children Aged <8 Years by Treatment in Overall Study, Using DCOA 1 Questionnaire

    Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by caregiver for children under 8 years. Participants were asked 2 questions from Section I of the IPAQ PRO tool related to participant's assessment of signs and used a 11-point scale: 0=no bruising to 10=worst possible bruising and 0=no bleeding to 10=worst possible bleeding, respectively. The total score was sum of all questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for assessment of signs meant a better outcome.

    Time frame: Baseline up to Week 24

  15. Total Scores Related to Caregiver Life Interference, Including Family Life Interference Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire

    Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by caregiver. Participants were asked 13 questions from Section I of the IPAQ PRO tool related to caregiver life interference and used a 5-point scale: 1= never to 5= always. The total score ranged was sum of scores from all questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for caregiver and family life interference meant less life interference (a better outcome).

    Time frame: Baseline, Week 12, Week 24

  16. Total Scores Related to Caregiver Life Interference, Including Family Life Interference by Treatment in Overall Study, Using DCOA 1 Questionnaire

    Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by caregiver. Participants were asked 13 questions from Section I of the IPAQ PRO tool related to caregiver life interference and used a 5-point scale: 1= never to 5= always. The total score ranged was sum of scores from all questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for caregiver and family life interference meant less life interference (a better outcome).

    Time frame: Baseline up to Week 24

  17. Total Scores Related to Missed Injections Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire

    Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to number of missed injections (daily or weekly administration) during past 4 weeks. The total scores ranged from 0 to 31 for daily administration (Genotropin) and from 0 to 5 for weekly administration (Somatrogon). All scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for missed injections meant a better outcome.

    Time frame: Baseline, Week 12, Week 24

  18. Total Scores Related to Missed Injections by Treatment in Overall Study, Using DCOA 1 Questionnaire

    Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to number of missed injections (daily or weekly administration) during past 4 weeks. The total scores ranged from 0 to 31 for daily administration (Genotropin) and from 0 to 5 for weekly administration (Somatrogon). All scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for missed injections meant a better outcome.

    Time frame: Baseline up to Week 24

  19. Number of Participants as Per Responses to Choice of Injection Pen Assessed at Week 24, Using DCOA 2 Questionnaire

    Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregivers responded to question from Section II of the IPAQ PRO tool "If you were given the choice between the daily growth hormone injection pen and the weekly growth hormone injection pen, which pen would you choose?" Response was: 1) the daily injection pen (Genotropin) or 2) the weekly injection pen (Somatrogon).

    Time frame: Week 24

  20. Number of Participants as Per Responses to Preferred Injection Schedule Assessed at Week 24, Using DCOA 2 Questionnaire

    Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregivers responded to question from Section II of the IPAQ PRO tool "Which growth hormone injection schedule do you prefer overall?" by choosing from any 1 option from: 1) prefer the weekly injection schedule (Somatrogon); 2) prefer the daily injection schedule (Genotropin); 3) no preference.

    Time frame: Week 24

  21. Number of Participants as Per Responses to Convenience of the Injection Schedule Assessed at Week 24, Using DCOA 2 Questionnaire

    Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregivers responded to question from Section II of the IPAQ PRO tool "Which growth hormone injection schedule was more convenient overall?" by choosing from any 1 option from: 1) weekly injection schedule was more convenient (Somatrogon); 2) daily injection schedule was more convenient (Genotropin); 3) no difference.

    Time frame: Week 24

  22. Number of Participants as Per Responses to Ease of Following Injection Schedule Assessed at Week 24, Using DCOA 2 Questionnaire

    Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregivers responded to question from Section II of the IPAQ PRO tool "Which growth hormone injection schedule was easier to follow overall?" by choosing from any 1 option from: 1) easier to follow weekly injection schedule (Somatrogon); 2) easier to follow daily injection schedule (Genotropin); 3) no difference.

    Time frame: Week 24

  23. Number of Participants as Per Responses to Pen Ease of Use Assessed at Week 24, Using DCOA 2 Questionnaire

    Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregiver were asked a question "Which pen was easier to use?" from Section II of the IPAQ PRO tool. Question had 4 parts: preparing the injection pen (Part I), setting the dose (Part II), injecting the medicine (Part III) and storing the pen (Part IV). Participants/caregiver expressed their preference by choosing from any 1 option for each activity from: 1) weekly pen easier to use (Somatrogon); 2) daily pen easier to use (Genotropin); 3) no difference.

    Time frame: Week 24

  24. Number of Participants as Per Responses to Participant Life Interference Assessed at Week 24, Using DCOA 2 Questionnaire

    Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregiver were asked a question "Which injection schedule interfered less?" from Section II of the IPAQ PRO tool related to participant life interference. Participants were assessed for 5 activities: daily activities (Activity 1), social activities (Activity 2), recreation/leisure activities (Activity 3), spending night away from home (Activity 4) and travel (Activity 5). The participants expressed their preference by choosing from any 1 option for each activity from: 1) weekly injection schedule interfered less (Somatrogon); 2) daily injection schedule interfered less (Genotropin); 3) no difference.

    Time frame: Week 24

  25. Number of Participants as Per Responses to Caregiver Life Interference Assessed at Week 24, Using DCOA 2 Questionnaire

    Caregivers of participants were asked a question "Which injection schedule interfered less?" from Section II of the IPAQ PRO tool related to caregiver life interference and were assessed for 5 activities: daily activities (Activity 1), social activities (Activity 2), recreation/leisure activities (Activity 3), spending night away from home (Activity 4) and travel (Activity 5). Preference was expressed by choosing from any 1 option for each activity from: 1) weekly injection schedule interfered less (Somatrogon); 2) daily injection schedule interfered less (Genotropin); 3) no difference. The caregivers responded for the participants, and in actual they respond to the number of participants only but per caregiver responses.

    Time frame: Week 24

  26. Number of Participants as Per Responses to Family Life Interference Assessed at Week 24, Using DCOA 2 Questionnaire

    Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/ caregiver were asked a question "Which injection schedule interfered less?" from Section II of the IPAQ PRO tool related to family life interference and assessed for 5 activities: daily activities (Activity 1), social activities (Activity 2), recreation/leisure activities (Activity 3), spending night away from home (Activity 4) and travel (Activity 5). Preference was expressed by choosing from any 1 option for each activity from: 1) weekly injection schedule interfered less (Somatrogon); 2) daily injection schedule interfered less (Genotropin); 3) no difference.

    Time frame: Week 24

  27. Number of Participants as Per Response to Benefit Relating to the Injection Schedule Assessed at Week 24, Using DCOA 2 Questionnaire

    Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregiver were asked a question "How beneficial was to take injections less often?" from Section II of the IPAQ PRO tool pertaining to benefit relating to the Injection schedule and used a 5-point scale: 1= extremely beneficial, 2= very beneficial, 3= moderately beneficial, 4= slightly beneficial and 5= not at all beneficial. Lower score of benefit relating to injection schedule meant a better outcome.

    Time frame: Week 24

  28. Number of Participants as Per Responses to Intention to Comply Assessed at Week 24, Using DCOA 2 Questionnaire

    Participants/caregiver dyads were asked 4 questions "Which schedule would be better able to follow?" (Question 1), "Which schedule would be more likely to follow for a longer time?" (Question 2), "Which schedule would be better able to follow for a longer time?" (Question 3) and "Which schedule would be more likely to follow?" (Question 4) from Section II of the IPAQ PRO tool related to participant intention to comply with treatment. Options for each question were: 1) weekly injection (Somatrogon) 2) daily injection (Genotropin), or 3) no difference.

    Time frame: Week 24

  29. Patient Global Impression Severity-Impact on Daily Activities (PGIS-IDA) Score Assessed at Baseline, Week 12 and Week 24

    The PGIS-IDA rated the severity of the impact on daily activities due to the treatment administration during the past 4 weeks on a 7-point scale (1= not present to 7= extremely severe). Scores were transformed from raw scores to a 0 to 100 scale. Lower scores meant less impact on daily activities (better outcome).

    Time frame: Baseline, Week 12, Week 24

  30. Patient Global Impression Severity-Impact on Daily Activities (PGIS-IDA) Score by Treatment in Overall Study

    The PGIS-IDA rated the severity of the impact on daily activities due to the treatment administration during the past 4 weeks on a 7-point scale (1= not present to 7= extremely severe). Scores were transformed from raw scores to a 0 to 100 scale. Lower scores meant less impact on daily activities (better outcome).

    Time frame: Baseline up to Week 24

Other outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-Emergent Treatment Related AEs and SAEs

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Treatment-emergent AEs (TEAEs) were defined as events that occurred between first dose of study drug up to 35 days after last dose of study drug. Related TEAEs were those AEs who had relation to the study treatment and was judged by investigator.

    Time frame: Baseline up to 35 days after last dose of study drug (up to 29 Weeks)

  2. Number of Participants With Adverse Events According to Severity

    AEs were assessed and categorized according to the severity as mild (did not interfered with participant's usual function), moderate (interfered to some extent with participant's usual function) and severe (interfered significantly with participant's usual function).

    Time frame: Baseline up to 35 days after last dose of study drug (up to 29 Weeks)

  3. Number of Participants With Discontinuation Due to Adverse Events (AEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. The discontinuations due to adverse events was defined for participants and reported in this outcome measure.

    Time frame: Baseline up to 35 days after last dose of study drug (up to 29 Weeks)

  4. Number of Participants With Laboratory Abnormalities

    The laboratory abnormality parameters included Hematology: erythrocyte (Er.) mean corpuscular volume, Er. mean corpuscular hemoglobin:\<0.9\*lower limit normal (LLN), leukocytes:\<0.6\*LLN, lymphocytes:\<0.8\*LLN, neutrophils:\<0.8\*LLN, greater than (\>) 1.2\*upper limit normal (ULN), eosinophils, monocytes:\>1.2\*ULN. Clinical chemistry: bilirubin, direct bilirubin, indirect bilirubin:\>1.5\*ULN, gamma glutamyl transferase:\>3.0\*ULN, albumin:\>1.2\*ULN, blood urea nitrogen:\>1.3\*ULN, urate:\>1.2\*ULN, high-density lipoprotein (HDL) cholesterol:\<0.8\*LLN, potassium, magnesium:\>1.1\*ULN, phosphate:\>1.2\*ULN, bicarbonate:\<0.9\*LLN, creatine kinase:\>2.0\*ULN. Urinalysis: specific gravity:\>1.030, ketones, urine protein, urine hemoglobin, nitrite, leukocyte esterase:\>=1.

    Time frame: Week 1 to Week 12, Week 13 to Week 24

  5. Number of Participants With Positive Anti-Recombinant Human Growth Hormone (rhGH) Antibodies and Neutralizing Antibodies (NAb)

    Blood samples were collected for determination of rhGH and NAb. The participants who tested positive for antibodies were reported.

    Time frame: Baseline, Week 12, Week 24

  6. Number of Participants With Positive Anti-Somatrogon Antibodies and Neutralizing Antibodies (NAb)

    Blood samples were collected for determination of anti-somatrogon antibodies and NAb. The participants who tested positive for antibodies were reported.

    Time frame: Baseline, Week 12, Week 24

07

Results

Posted Oct 14, 2021

Participant flow

Period 1 (12 Weeks)
Participant flow — Period 1 (12 Weeks)
MilestoneDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Started4344
Completed4343
Not completed01
Withdrew: Adverse event, not serious01
Period 2 (12 Weeks)
Participant flow — Period 2 (12 Weeks)
MilestoneDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Started4343
Completed4342
Not completed01
Withdrew: Protocol deviation01
Follow-up (5 Weeks)
Participant flow — Follow-up (5 Weeks)
MilestoneDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Started4343
Completed4343
Not completed00

Outcome measures

PrimaryTotal Score Related to Overall Life Interference Assessed at Baseline, Using Dyad Clinical Outcomes Assessment 1 (DCOA 1) Questionnaire

Participants were assessed for their treatment burden using DCOA 1 questionnaire completed by participant/caregiver dyads. The participant life interference questionnaire component of the DCOA 1 had 7 questions (life interference \[5 questions\]: a measure of life interference \[daily activities/social activities/leisure/night away from home/travel\]; life interference-changes to life routine \[1 question\]: a measure of how often changes are made to life routine; and life interference-bother of growth hormone \[GH\] injections \[1 question\]: a measure of how often the growth hormone injections cause bother) and all questions used a 5-point scale: 1= never, 2= rarely, 3= sometimes, 4= often, 5= always. The overall life interference total score was sum of all 7 questions, scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant less life interference (better outcome).

Time frame:
Baseline
Reported as:
Mean · units on a scale
Total Score Related to Overall Life Interference Assessed at Baseline, Using Dyad Clinical Outcomes Assessment 1 (DCOA 1) Questionnaire
units on a scaleDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Total Score Related to Overall Life Interference Assessed at Baseline, Using Dyad Clinical Outcomes Assessment 1 (DCOA 1) Questionnaire29.5 ± 18.027.1 ± 19.8
PrimaryTotal Score Related to Overall Life Interference Assessed at Week 12, Using DCOA 1 Questionnaire

Participants were assessed for their treatment burden using DCOA 1 questionnaire completed by participant/caregiver dyads. The participant life interference questionnaire component of the DCOA 1 had 7 questions (life interference \[5 questions\]: a measure of life interference \[daily activities/social activities/leisure/night away from home/travel\]; life interference-changes to life routine \[1 question\]: a measure of how often changes are made to life routine; and life interference-bother of growth hormone \[GH\] injections \[1 question\]: a measure of how often the growth hormone injections cause bother) and all questions used a 5-point scale: 1= never, 2= rarely, 3= sometimes, 4= often, 5= always. The overall life interference total score was sum of all 7 questions, scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant less life interference (better outcome).

Time frame:
Week 12
Reported as:
Mean · units on a scale
Total Score Related to Overall Life Interference Assessed at Week 12, Using DCOA 1 Questionnaire
units on a scaleDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Total Score Related to Overall Life Interference Assessed at Week 12, Using DCOA 1 Questionnaire25.2 ± 17.37.1 ± 7.8
PrimaryTotal Score Related to Overall Life Interference Assessed at Week 24, Using DCOA 1 Questionnaire

Participants were assessed for their treatment burden using DCOA 1 questionnaire completed by participant/caregiver dyads. The participant life interference questionnaire component of the DCOA 1 had 7 questions (life interference \[5 questions\]: a measure of life interference \[daily activities/social activities/leisure/night away from home/travel\]; life interference-changes to life routine \[1 question\]: a measure of how often changes are made to life routine; and life interference-bother of growth hormone \[GH\] injections \[1 question\]: a measure of how often the growth hormone injections cause bother) and all questions used a 5-point scale: 1= never, 2= rarely, 3= sometimes, 4= often, 5= always. The overall life interference total score was sum of all 7 questions, scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant less life interference (better outcome).

Time frame:
Week 24
Reported as:
Mean · units on a scale
Total Score Related to Overall Life Interference Assessed at Week 24, Using DCOA 1 Questionnaire
units on a scaleDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Total Score Related to Overall Life Interference Assessed at Week 24, Using DCOA 1 Questionnaire9.5 ± 13.323.0 ± 22.6
PrimaryTotal Score Related to Overall Life Interference by Treatment in Overall Study, Using DCOA 1 Questionnaire

Participants were assessed for their treatment burden using DCOA 1 questionnaire completed by participant/caregiver dyads. The participant life interference questionnaire component of the DCOA 1 had 7 questions (life interference \[5 questions\]: a measure of life interference \[daily activities/social activities/leisure/night away from home/travel\]; life interference-changes to life routine \[1 question\]: a measure of how often changes are made to life routine; and life interference-bother of growth hormone \[GH\] injections \[1 question\]: a measure of how often the growth hormone injections cause bother) and all questions used a 5-point scale: 1= never, 2= rarely, 3= sometimes, 4= often, 5= always. The overall life interference total score was sum of all 7 questions, scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant less life interference (better outcome).

Time frame:
Baseline up to Week 24
Reported as:
Mean · units on a scale
Total Score Related to Overall Life Interference by Treatment in Overall Study, Using DCOA 1 Questionnaire
units on a scaleGenotropinSomatrogon
Total Score Related to Overall Life Interference by Treatment in Overall Study, Using DCOA 1 Questionnaire24.13 (20.61 to 27.65)8.63 (5.05 to 12.22)
Statistical analysis
  • Genotropin vs Somatrogon · Mixed Models Analysis · p = <0.0001 (95% CI: Model-based difference in means. Results were based on a linear mixed effects model including sequence, period, and treatment as fixed effects and participant within sequence and within-participant error as random effects.) · Mean difference (final values): -15.49 · 95% CI -19.71 to -11.27
SecondaryTotal Score Related to Pen Ease of Use Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire

Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked 5 questions from Section I of the Injection Pen Assessment Questionnaire (IPAQ) patient-reported outcome (PRO) tool related to pen ease of use and used a 5-point scale: 1= very easy, 2= somewhat easy, 3= neither easy nor difficult, 4= somewhat difficult, 5= very difficult. The total score related to pen ease of use was sum of all 5 questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · units on a scale
Total Score Related to Pen Ease of Use Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire
units on a scaleDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Baseline10.6 ± 11.311.6 ± 12.8
Week 1212.0 ± 13.85.1 ± 7.6
Week 245.5 ± 9.39.4 ± 13.0
SecondaryTotal Score Related to Pen Ease of Use by Treatment in Overall Study, Using DCOA 1 Questionnaire

Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked 5 questions from Section I of the IPAQ PRO tool related to pen ease of use and used a 5-point scale: 1= very easy, 2= somewhat easy, 3= neither easy nor difficult, 4= somewhat difficult, 5= very difficult. The total score related to pen ease of use was sum of all 5 questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.

Time frame:
Baseline up to Week 24
Reported as:
Mean · units on a scale
Total Score Related to Pen Ease of Use by Treatment in Overall Study, Using DCOA 1 Questionnaire
units on a scaleGenotropinSomatrogon
Total Score Related to Pen Ease of Use by Treatment in Overall Study, Using DCOA 1 Questionnaire10.71 (8.27 to 13.14)5.32 (2.84 to 7.80)
Statistical analysis
  • Genotropin vs Somatrogon · Mixed Models Analysis · p = 0.0017 (95% CI: Model-based difference in means. Results were based on a linear mixed effects model including sequence, period, and treatment as fixed effects and participant within sequence and within-participant error as random effects.) · Mean difference (final values): -5.39 · 95% CI -8.69 to -2.09
SecondaryTotal Score Related to Ease of the Injection Schedule Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire

Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to ease of injection schedule and used a 5-point scale: 1= very easy, 2= somewhat easy, 3= neither easy nor difficult, 4= somewhat difficult, 5= very difficult. The total score related to ease of the injection schedule ranged from 1 to 5; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · units on a scale
Total Score Related to Ease of the Injection Schedule Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire
units on a scaleDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Baseline18.5 ± 20.016.3 ± 17.5
Week 1223.3 ± 25.24.4 ± 11.2
Week 249.5 ± 18.317.9 ± 22.3
SecondaryTotal Score Related to Ease of the Injection Schedule by Treatment in Overall Study, Using DCOA 1 Questionnaire

Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to ease of injection schedule and used a 5-point scale: 1= very easy, 2= somewhat easy, 3= neither easy nor difficult, 4= somewhat difficult, 5= very difficult. The total score related to ease of the injection schedule ranged from 1 to 5; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.

Time frame:
Baseline up to Week 24
Reported as:
Mean · units on a scale
Total Score Related to Ease of the Injection Schedule by Treatment in Overall Study, Using DCOA 1 Questionnaire
units on a scaleGenotropinSomatrogon
Total Score Related to Ease of the Injection Schedule by Treatment in Overall Study, Using DCOA 1 Questionnaire20.56 (16.22 to 24.89)6.96 (2.54 to 11.37)
Statistical analysis
  • Genotropin vs Somatrogon · Mixed Models Analysis · p = <0.0001 (95% CI: Model-based difference in means. Results were based on a linear mixed effects model including sequence, period, and treatment as fixed effects and participant within sequence and within-participant error as random effects.) · Mean difference (final values): -13.60 · 95% CI -19.74 to -7.45
SecondaryTotal Score Related to Convenience of the Injection Schedule Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire

Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to ease of injection schedule and used a 7-point scale: 1=extremely convenient to 7=extremely inconvenient. The total score related to convenience of injection schedule ranged from 1 to 7; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · units on a scale
Total Score Related to Convenience of the Injection Schedule Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire
units on a scaleDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Baseline34.5 ± 21.032.5 ± 21.3
Week 1235.3 ± 23.97.9 ± 10.7
Week 2411.9 ± 14.433.3 ± 24.1
SecondaryTotal Score Related to Convenience of the Injection Schedule by Treatment in Overall Study, Using DCOA 1 Questionnaire

Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to ease of injection schedule and used a 7-point scale: 1=extremely convenient to 7=extremely inconvenient. The total score related to convenience of injection schedule ranged from 1 to 7; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.

Time frame:
Baseline up to Week 24
Reported as:
Mean · units on a scale
Total Score Related to Convenience of the Injection Schedule by Treatment in Overall Study, Using DCOA 1 Questionnaire
units on a scaleGenotropinSomatrogon
Total Score Related to Convenience of the Injection Schedule by Treatment in Overall Study, Using DCOA 1 Questionnaire34.30 (30.13 to 38.47)9.96 (5.71 to 14.21)
Statistical analysis
  • Genotropin vs Somatrogon · Mixed Models Analysis · p = <0.0001 (95% CI: Model-based difference in means. Results were based on a linear mixed effects model including sequence, period, and treatment as fixed effects and participant within sequence and within-participant error as random effects.) · Mean difference (final values): -24.34 · 95% CI -30.10 to -18.57
SecondaryTotal Score Related to Satisfaction With Overall Treatment Experience Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire

Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to participant satisfaction with treatment and used a 5-point scale: 1=very satisfied to 5=very dissatisfied. The total score related to satisfaction with overall treatment ranged from 1 to 5; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · units on a scale
Total Score Related to Satisfaction With Overall Treatment Experience Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire
units on a scaleDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Baseline28.0 ± 21.529.4 ± 23.3
Week 1227.3 ± 27.220.0 ± 31.1
Week 2422.0 ± 32.330.4 ± 27.9
SecondaryTotal Score Related to Satisfaction With Overall Treatment Experience by Treatment in Overall Study, Using DCOA 1 Questionnaire

Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to participant satisfaction with treatment and used a 5-point scale: 1=very satisfied to 5=very dissatisfied. The total score related to satisfaction with overall treatment ranged from 1 to 5; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.

Time frame:
Baseline up to Week 24
Reported as:
Mean · units on a scale
Total Score Related to Satisfaction With Overall Treatment Experience by Treatment in Overall Study, Using DCOA 1 Questionnaire
units on a scaleGenotropinSomatrogon
Total Score Related to Satisfaction With Overall Treatment Experience by Treatment in Overall Study, Using DCOA 1 Questionnaire28.95 (22.55 to 35.36)21.13 (14.61 to 27.65)
Statistical analysis
  • Genotropin vs Somatrogon · Mixed Models Analysis · p = 0.0739 (95% CI: Model-based difference in means. Results were based on a linear mixed effects model including sequence, period, and treatment as fixed effects and participant within sequence and within-participant error as random effects.) · Mean difference (final values): -7.83 · 95% CI -16.42 to 0.77
SecondaryTotal Scores Related to Willingness to Continue Injection Schedule Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire

Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to participant willingness to continue treatment and used a 5-point scale: 1=extremely willing to 5=not at all willing. The total score related to willingness to continue injection schedule ranged from 1 to 5; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · units on a scale
Total Scores Related to Willingness to Continue Injection Schedule Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire
units on a scaleDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Baseline18.5 ± 20.022.5 ± 23.9
Week 1228.5 ± 27.610.6 ± 21.1
Week 2413.1 ± 24.830.4 ± 29.0
SecondaryTotal Scores Related to Willingness to Continue Injection Schedule by Treatment in Overall Study, Using DCOA 1 Questionnaire

Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to participant willingness to continue treatment and used a 5-point scale: 1=extremely willing to 5=not at all willing. The total score related to willingness to continue injection schedule ranged from 1 to 5; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.

Time frame:
Baseline up to Week 24
Reported as:
Mean · units on a scale
Total Scores Related to Willingness to Continue Injection Schedule by Treatment in Overall Study, Using DCOA 1 Questionnaire
units on a scaleGenotropinSomatrogon
Total Scores Related to Willingness to Continue Injection Schedule by Treatment in Overall Study, Using DCOA 1 Questionnaire29.54 (23.95 to 35.12)11.93 (6.24 to 17.62)
Statistical analysis
  • Genotropin vs Somatrogon · Mixed Models Analysis · p = <0.0001 (95% CI: Model-based difference in means. Results were based on a linear mixed effects model including sequence, period, and treatment as fixed effects and participant within sequence and within-participant error as random effects.) · Mean difference (final values): -17.60 · 95% CI -25.15 to -10.06
SecondaryTotal Scores Related to Injection Signs and Symptoms for Participants Aged 8 Years and Above Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire

Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participants (8-17 years old). Participants were asked 4 questions from Section I of the IPAQ PRO tool related to participant's injection signs and symptoms and used a 11-point scale: 0=no pain to 10=worst possible pain; 0=no stinging to 10=worst possible stinging; 0=no bruising to 10=worst possible bruising; and 0=no bleeding to 10=worst possible bleeding, respectively. The total score was sum of all questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for injection signs and symptoms meant a better outcome.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · units on a scale
Total Scores Related to Injection Signs and Symptoms for Participants Aged 8 Years and Above Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire
units on a scaleDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Baseline15.0 ± 10.413.8 ± 11.9
Week 1216.2 ± 12.213.7 ± 10.3
Week 2413.6 ± 12.210.9 ± 9.6
SecondaryTotal Scores Related to Injection Signs and Symptoms for Participants Aged 8 Years and Above by Treatment in Overall Study, Using DCOA 1 Questionnaire

Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participants (8-17 years old). Participants were asked 4 questions from Section I of the IPAQ PRO tool related to participant's injection signs and symptoms and used a 11-point scale: 0=no pain to 10=worst possible pain; 0=no stinging to 10=worst possible stinging; 0=no bruising to 10=worst possible bruising; and 0=no bleeding to 10=worst possible bleeding, respectively. The total score was sum of all questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for injection signs and symptoms meant a better outcome.

Time frame:
Baseline up to Week 24
Reported as:
Mean · units on a scale
Total Scores Related to Injection Signs and Symptoms for Participants Aged 8 Years and Above by Treatment in Overall Study, Using DCOA 1 Questionnaire
units on a scaleGenotropinSomatrogon
Total Scores Related to Injection Signs and Symptoms for Participants Aged 8 Years and Above by Treatment in Overall Study, Using DCOA 1 Questionnaire13.56 (10.78 to 16.34)14.27 (11.32 to 17.21)
Statistical analysis
  • Genotropin vs Somatrogon · Mixed Models Analysis · p = 0.6137 (95% CI: Model-based difference in means. Results were based on a linear mixed effects model including sequence, period, and treatment as fixed effects and participant within sequence and within-participant error as random effects.) · Mean difference (final values): 0.71 · 95% CI -2.09 to 3.51
SecondaryTotal Scores Related to Assessment of Signs, Completed by Caregiver for Children Aged <8 Years Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire

Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by caregiver for children under 8 years. Participants were asked 2 questions from Section I of the IPAQ PRO tool related to participant's assessment of signs and used a 11-point scale: 0=no bruising to 10=worst possible bruising and 0=no bleeding to 10=worst possible bleeding, respectively. The total score was sum of all questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for assessment of signs meant a better outcome.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · units on a scale
Total Scores Related to Assessment of Signs, Completed by Caregiver for Children Aged <8 Years Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire
units on a scaleDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Baseline14.2 ± 14.613.5 ± 11.3
Week 129.3 ± 10.613.0 ± 15.8
Week 245.6 ± 7.89.4 ± 8.8
SecondaryTotal Scores Related to Assessment of Signs, Completed by Caregiver for Children Aged <8 Years by Treatment in Overall Study, Using DCOA 1 Questionnaire

Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by caregiver for children under 8 years. Participants were asked 2 questions from Section I of the IPAQ PRO tool related to participant's assessment of signs and used a 11-point scale: 0=no bruising to 10=worst possible bruising and 0=no bleeding to 10=worst possible bleeding, respectively. The total score was sum of all questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for assessment of signs meant a better outcome.

Time frame:
Baseline up to Week 24
Reported as:
Mean · units on a scale
Total Scores Related to Assessment of Signs, Completed by Caregiver for Children Aged <8 Years by Treatment in Overall Study, Using DCOA 1 Questionnaire
units on a scaleGenotropinSomatrogon
Total Scores Related to Assessment of Signs, Completed by Caregiver for Children Aged <8 Years by Treatment in Overall Study, Using DCOA 1 Questionnaire8.75 (2.65 to 14.86)9.31 (3.47 to 15.16)
Statistical analysis
  • Genotropin vs Somatrogon · Mixed Models Analysis · p = 0.8404 (95% CI: Model-based difference in means. Results were based on a linear mixed effects model including sequence, period, and treatment as fixed effects and participant within sequence and within-participant error as random effects.) · Mean difference (final values): 0.56 · 95% CI -5.29 to 6.41
SecondaryTotal Scores Related to Caregiver Life Interference, Including Family Life Interference Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire

Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by caregiver. Participants were asked 13 questions from Section I of the IPAQ PRO tool related to caregiver life interference and used a 5-point scale: 1= never to 5= always. The total score ranged was sum of scores from all questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for caregiver and family life interference meant less life interference (a better outcome).

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · units on a scale
Total Scores Related to Caregiver Life Interference, Including Family Life Interference Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire
units on a scaleDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Baseline17.8 ± 17.520.0 ± 20.1
Week 1215.9 ± 16.73.1 ± 5.5
Week 243.8 ± 6.018.1 ± 23.4
SecondaryTotal Scores Related to Caregiver Life Interference, Including Family Life Interference by Treatment in Overall Study, Using DCOA 1 Questionnaire

Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by caregiver. Participants were asked 13 questions from Section I of the IPAQ PRO tool related to caregiver life interference and used a 5-point scale: 1= never to 5= always. The total score ranged was sum of scores from all questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for caregiver and family life interference meant less life interference (a better outcome).

Time frame:
Baseline up to Week 24
Reported as:
Mean · units on a scale
Total Scores Related to Caregiver Life Interference, Including Family Life Interference by Treatment in Overall Study, Using DCOA 1 Questionnaire
units on a scaleGenotropinSomatrogon
Total Scores Related to Caregiver Life Interference, Including Family Life Interference by Treatment in Overall Study, Using DCOA 1 Questionnaire17.01 (13.77 to 20.25)3.54 (0.24 to 6.84)
Statistical analysis
  • Genotropin vs Somatrogon · Mixed Models Analysis · p = <0.0001 (95% CI: Model-based difference in means. Results were based on a linear mixed effects model including sequence, period, and treatment as fixed effects and participant within sequence and within-participant error as random effects.) · Mean difference (final values): -13.47 · 95% CI -17.59 to -9.35
SecondaryTotal Scores Related to Missed Injections Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire

Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to number of missed injections (daily or weekly administration) during past 4 weeks. The total scores ranged from 0 to 31 for daily administration (Genotropin) and from 0 to 5 for weekly administration (Somatrogon). All scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for missed injections meant a better outcome.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · units on a scale
Total Scores Related to Missed Injections Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire
units on a scaleDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Baseline7.8 ± 15.17.3 ± 16.1
Week 124.3 ± 8.20.0 ± 0.0
Week 241.9 ± 7.43.1 ± 10.8
SecondaryTotal Scores Related to Missed Injections by Treatment in Overall Study, Using DCOA 1 Questionnaire

Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to number of missed injections (daily or weekly administration) during past 4 weeks. The total scores ranged from 0 to 31 for daily administration (Genotropin) and from 0 to 5 for weekly administration (Somatrogon). All scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for missed injections meant a better outcome.

Time frame:
Baseline up to Week 24
Reported as:
Mean · units on a scale
Total Scores Related to Missed Injections by Treatment in Overall Study, Using DCOA 1 Questionnaire
units on a scaleGenotropinSomatrogon
Total Scores Related to Missed Injections by Treatment in Overall Study, Using DCOA 1 Questionnaire3.71 (2.03 to 5.39)0.95 (-0.76 to 2.66)
Statistical analysis
  • Genotropin vs Somatrogon · Mixed Models Analysis · p = 0.0245 (95% CI: Model-based difference in means. Results were based on a linear mixed effects model including sequence, period, and treatment as fixed effects and participant within sequence and within-participant error as random effects.) · Mean difference (final values): -2.76 · 95% CI -5.16 to -0.36
SecondaryNumber of Participants as Per Responses to Choice of Injection Pen Assessed at Week 24, Using DCOA 2 Questionnaire

Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregivers responded to question from Section II of the IPAQ PRO tool "If you were given the choice between the daily growth hormone injection pen and the weekly growth hormone injection pen, which pen would you choose?" Response was: 1) the daily injection pen (Genotropin) or 2) the weekly injection pen (Somatrogon).

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants as Per Responses to Choice of Injection Pen Assessed at Week 24, Using DCOA 2 Questionnaire
ParticipantsDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Somatrogon3836
Genotropin46
SecondaryNumber of Participants as Per Responses to Preferred Injection Schedule Assessed at Week 24, Using DCOA 2 Questionnaire

Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregivers responded to question from Section II of the IPAQ PRO tool "Which growth hormone injection schedule do you prefer overall?" by choosing from any 1 option from: 1) prefer the weekly injection schedule (Somatrogon); 2) prefer the daily injection schedule (Genotropin); 3) no preference.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants as Per Responses to Preferred Injection Schedule Assessed at Week 24, Using DCOA 2 Questionnaire
ParticipantsDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Somatrogon4037
Genotropin24
No Preference01
SecondaryNumber of Participants as Per Responses to Convenience of the Injection Schedule Assessed at Week 24, Using DCOA 2 Questionnaire

Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregivers responded to question from Section II of the IPAQ PRO tool "Which growth hormone injection schedule was more convenient overall?" by choosing from any 1 option from: 1) weekly injection schedule was more convenient (Somatrogon); 2) daily injection schedule was more convenient (Genotropin); 3) no difference.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants as Per Responses to Convenience of the Injection Schedule Assessed at Week 24, Using DCOA 2 Questionnaire
ParticipantsDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Somatrogon4040
Genotropin22
No Difference00
SecondaryNumber of Participants as Per Responses to Ease of Following Injection Schedule Assessed at Week 24, Using DCOA 2 Questionnaire

Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregivers responded to question from Section II of the IPAQ PRO tool "Which growth hormone injection schedule was easier to follow overall?" by choosing from any 1 option from: 1) easier to follow weekly injection schedule (Somatrogon); 2) easier to follow daily injection schedule (Genotropin); 3) no difference.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants as Per Responses to Ease of Following Injection Schedule Assessed at Week 24, Using DCOA 2 Questionnaire
ParticipantsDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Somatrogon3834
Genotropin44
No Difference04
SecondaryNumber of Participants as Per Responses to Pen Ease of Use Assessed at Week 24, Using DCOA 2 Questionnaire

Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregiver were asked a question "Which pen was easier to use?" from Section II of the IPAQ PRO tool. Question had 4 parts: preparing the injection pen (Part I), setting the dose (Part II), injecting the medicine (Part III) and storing the pen (Part IV). Participants/caregiver expressed their preference by choosing from any 1 option for each activity from: 1) weekly pen easier to use (Somatrogon); 2) daily pen easier to use (Genotropin); 3) no difference.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants as Per Responses to Pen Ease of Use Assessed at Week 24, Using DCOA 2 Questionnaire
ParticipantsDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Part I: Somatrogon2925
Part I: Genotropin34
Part I: No difference1013
Part II: Somatrogon2117
Part II: Genotropin68
Part II: No Difference1517
Part III: Somatrogon1318
Part III: Genotropin1612
Part III: No Difference1312
Part IV: Somatrogon1214
Part IV: Genotropin22
Part IV: No Difference2826
SecondaryNumber of Participants as Per Responses to Participant Life Interference Assessed at Week 24, Using DCOA 2 Questionnaire

Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregiver were asked a question "Which injection schedule interfered less?" from Section II of the IPAQ PRO tool related to participant life interference. Participants were assessed for 5 activities: daily activities (Activity 1), social activities (Activity 2), recreation/leisure activities (Activity 3), spending night away from home (Activity 4) and travel (Activity 5). The participants expressed their preference by choosing from any 1 option for each activity from: 1) weekly injection schedule interfered less (Somatrogon); 2) daily injection schedule interfered less (Genotropin); 3) no difference.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants as Per Responses to Participant Life Interference Assessed at Week 24, Using DCOA 2 Questionnaire
ParticipantsDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Activity 1: Somatrogon3531
Activity 1: Genotropin21
Activity 1: No Difference510
Activity 2: Somatrogon3434
Activity 2: Genotropin20
Activity 2: No Difference68
Activity 3: Somatrogon3433
Activity 3: Genotropin21
Activity 3: No Difference68
Activity 4: Somatrogon3637
Activity 4: Genotropin21
Activity 4: No Difference44
Activity 5: Somatrogon3337
Activity 5: Genotropin30
Activity 5: No Difference65
SecondaryNumber of Participants as Per Responses to Caregiver Life Interference Assessed at Week 24, Using DCOA 2 Questionnaire

Caregivers of participants were asked a question "Which injection schedule interfered less?" from Section II of the IPAQ PRO tool related to caregiver life interference and were assessed for 5 activities: daily activities (Activity 1), social activities (Activity 2), recreation/leisure activities (Activity 3), spending night away from home (Activity 4) and travel (Activity 5). Preference was expressed by choosing from any 1 option for each activity from: 1) weekly injection schedule interfered less (Somatrogon); 2) daily injection schedule interfered less (Genotropin); 3) no difference. The caregivers responded for the participants, and in actual they respond to the number of participants only but per caregiver responses.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants as Per Responses to Caregiver Life Interference Assessed at Week 24, Using DCOA 2 Questionnaire
ParticipantsDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Activity 1: Somatrogon3631
Activity 1: Genotropin20
Activity 1: No Difference411
Activity 2: Somatrogon3632
Activity 2: Genotropin20
Activity 2: No Difference410
Activity 3: Somatrogon3534
Activity 3: Genotropin20
Activity 3: No Difference58
Activity 4: Somatrogon3537
Activity 4: Genotropin10
Activity 4: No Difference65
Activity 5: Somatrogon3537
Activity 5: Genotropin20
Activity 5: No Difference55
SecondaryNumber of Participants as Per Responses to Family Life Interference Assessed at Week 24, Using DCOA 2 Questionnaire

Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/ caregiver were asked a question "Which injection schedule interfered less?" from Section II of the IPAQ PRO tool related to family life interference and assessed for 5 activities: daily activities (Activity 1), social activities (Activity 2), recreation/leisure activities (Activity 3), spending night away from home (Activity 4) and travel (Activity 5). Preference was expressed by choosing from any 1 option for each activity from: 1) weekly injection schedule interfered less (Somatrogon); 2) daily injection schedule interfered less (Genotropin); 3) no difference.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants as Per Responses to Family Life Interference Assessed at Week 24, Using DCOA 2 Questionnaire
ParticipantsDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Activity 1: Somatrogon3229
Activity 1: Genotropin10
Activity 1: No Difference913
Activity 2: Somatrogon3230
Activity 2: Genotropin10
Activity 2: No Difference912
Activity 3: Somatrogon3232
Activity 3: Genotropin10
Activity 3: No Difference910
Activity 4: Somatrogon3134
Activity 4: Genotropin10
Activity 4: No Difference108
Activity 5: Somatrogon3136
Activity 5: Genotropin10
Activity 5: No Difference106
SecondaryNumber of Participants as Per Response to Benefit Relating to the Injection Schedule Assessed at Week 24, Using DCOA 2 Questionnaire

Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregiver were asked a question "How beneficial was to take injections less often?" from Section II of the IPAQ PRO tool pertaining to benefit relating to the Injection schedule and used a 5-point scale: 1= extremely beneficial, 2= very beneficial, 3= moderately beneficial, 4= slightly beneficial and 5= not at all beneficial. Lower score of benefit relating to injection schedule meant a better outcome.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants as Per Response to Benefit Relating to the Injection Schedule Assessed at Week 24, Using DCOA 2 Questionnaire
ParticipantsDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Extremely Beneficial2820
Very Beneficial1114
Moderately Beneficial13
Slightly Beneficial03
Not At All Beneficial22
SecondaryNumber of Participants as Per Responses to Intention to Comply Assessed at Week 24, Using DCOA 2 Questionnaire

Participants/caregiver dyads were asked 4 questions "Which schedule would be better able to follow?" (Question 1), "Which schedule would be more likely to follow for a longer time?" (Question 2), "Which schedule would be better able to follow for a longer time?" (Question 3) and "Which schedule would be more likely to follow?" (Question 4) from Section II of the IPAQ PRO tool related to participant intention to comply with treatment. Options for each question were: 1) weekly injection (Somatrogon) 2) daily injection (Genotropin), or 3) no difference.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants as Per Responses to Intention to Comply Assessed at Week 24, Using DCOA 2 Questionnaire
ParticipantsDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Question 1: Somatrogon3331
Question 1: Genotropin22
Question 1: No Difference79
Question 2: Somatrogon2932
Question 2: Genotropin12
Question 2: No Difference128
Question 3: Somatrogon3435
Question 3: Genotropin11
Question 3: No Difference76
Question 4: Somatrogon2631
Question 4: Genotropin32
Question 4: No Difference139
SecondaryPatient Global Impression Severity-Impact on Daily Activities (PGIS-IDA) Score Assessed at Baseline, Week 12 and Week 24

The PGIS-IDA rated the severity of the impact on daily activities due to the treatment administration during the past 4 weeks on a 7-point scale (1= not present to 7= extremely severe). Scores were transformed from raw scores to a 0 to 100 scale. Lower scores meant less impact on daily activities (better outcome).

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · units on a scale
Patient Global Impression Severity-Impact on Daily Activities (PGIS-IDA) Score Assessed at Baseline, Week 12 and Week 24
units on a scaleDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Baseline15.0 ± 14.816.3 ± 16.2
Week 1219.0 ± 19.44.6 ± 7.5
Week 247.1 ± 9.822.2 ± 20.4
SecondaryPatient Global Impression Severity-Impact on Daily Activities (PGIS-IDA) Score by Treatment in Overall Study

The PGIS-IDA rated the severity of the impact on daily activities due to the treatment administration during the past 4 weeks on a 7-point scale (1= not present to 7= extremely severe). Scores were transformed from raw scores to a 0 to 100 scale. Lower scores meant less impact on daily activities (better outcome).

Time frame:
Baseline up to Week 24
Reported as:
Mean · units on a scale
Patient Global Impression Severity-Impact on Daily Activities (PGIS-IDA) Score by Treatment in Overall Study
units on a scaleGenotropinSomatrogon
Patient Global Impression Severity-Impact on Daily Activities (PGIS-IDA) Score by Treatment in Overall Study20.64 (17.30 to 23.99)6.06 (2.66 to 9.46)
Statistical analysis
  • Genotropin vs Somatrogon · Mixed Models Analysis · p = <0.0001 (95% CI: Model-based difference in means. Results were based on a linear mixed effects model including sequence, period, and treatment as fixed effects and participant within sequence and within-participant error as random effects.) · Mean difference (final values): -14.58 · 95% CI -18.72 to -10.44
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-Emergent Treatment Related AEs and SAEs

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Treatment-emergent AEs (TEAEs) were defined as events that occurred between first dose of study drug up to 35 days after last dose of study drug. Related TEAEs were those AEs who had relation to the study treatment and was judged by investigator.

Time frame:
Baseline up to 35 days after last dose of study drug (up to 29 Weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-Emergent Treatment Related AEs and SAEs
ParticipantsGenotropinSomatrogon
Treatment-Emergent AEs3847
Treatment-Emergent SAEs00
Treatment-Emergent Related AEs1421
Treatment-Emergent Related SAEs00
Other pre-specifiedNumber of Participants With Adverse Events According to Severity

AEs were assessed and categorized according to the severity as mild (did not interfered with participant's usual function), moderate (interfered to some extent with participant's usual function) and severe (interfered significantly with participant's usual function).

Time frame:
Baseline up to 35 days after last dose of study drug (up to 29 Weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events According to Severity
ParticipantsGenotropinSomatrogon
Mild3441
Moderate46
Severe00
Other pre-specifiedNumber of Participants With Discontinuation Due to Adverse Events (AEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. The discontinuations due to adverse events was defined for participants and reported in this outcome measure.

Time frame:
Baseline up to 35 days after last dose of study drug (up to 29 Weeks)
Reported as:
Count of participants · Participants
Number of Participants With Discontinuation Due to Adverse Events (AEs)
ParticipantsGenotropinSomatrogon
Number of Participants With Discontinuation Due to Adverse Events (AEs)01
Other pre-specifiedNumber of Participants With Laboratory Abnormalities

The laboratory abnormality parameters included Hematology: erythrocyte (Er.) mean corpuscular volume, Er. mean corpuscular hemoglobin:\<0.9\*lower limit normal (LLN), leukocytes:\<0.6\*LLN, lymphocytes:\<0.8\*LLN, neutrophils:\<0.8\*LLN, greater than (\>) 1.2\*upper limit normal (ULN), eosinophils, monocytes:\>1.2\*ULN. Clinical chemistry: bilirubin, direct bilirubin, indirect bilirubin:\>1.5\*ULN, gamma glutamyl transferase:\>3.0\*ULN, albumin:\>1.2\*ULN, blood urea nitrogen:\>1.3\*ULN, urate:\>1.2\*ULN, high-density lipoprotein (HDL) cholesterol:\<0.8\*LLN, potassium, magnesium:\>1.1\*ULN, phosphate:\>1.2\*ULN, bicarbonate:\<0.9\*LLN, creatine kinase:\>2.0\*ULN. Urinalysis: specific gravity:\>1.030, ketones, urine protein, urine hemoglobin, nitrite, leukocyte esterase:\>=1.

Time frame:
Week 1 to Week 12, Week 13 to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities
ParticipantsDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Week 1 to Week 121919
Week 13 to Week 242421
Other pre-specifiedNumber of Participants With Positive Anti-Recombinant Human Growth Hormone (rhGH) Antibodies and Neutralizing Antibodies (NAb)

Blood samples were collected for determination of rhGH and NAb. The participants who tested positive for antibodies were reported.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-Recombinant Human Growth Hormone (rhGH) Antibodies and Neutralizing Antibodies (NAb)
ParticipantsDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Baseline: Anti-rhGH50
Baseline: Neutralizing00
Week 12: Anti-rhGH33
Week 12: Neutralizing00
Week 24: Anti-rhGH46
Week 24: Neutralizing00
Other pre-specifiedNumber of Participants With Positive Anti-Somatrogon Antibodies and Neutralizing Antibodies (NAb)

Blood samples were collected for determination of anti-somatrogon antibodies and NAb. The participants who tested positive for antibodies were reported.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-Somatrogon Antibodies and Neutralizing Antibodies (NAb)
ParticipantsDaily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily Genotropin
Baseline: Anti-Somatrogon Antibodies00
Baseline: Neutralizing00
Week 12: Anti-Somatrogon Antibodies—4
Week 12: Neutralizing—0
Week 24: Anti-Somatrogon Antibodies0—
Week 24: Neutralizing0—

Adverse events

Collected over Baseline up to 35 days after last dose of study drug (up to 29 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Genotropin0/86 (0%)0/86 (0%)38/86 (44.2%)
Somatrogon0/87 (0%)0/87 (0%)47/87 (54%)
Most frequent other events
Showing 10 of 67
Most frequent other events
EventGenotropinSomatrogon
Injection site painGeneral disorders11/8613/87
Injection site haematomaGeneral disorders8/864/87
NasopharyngitisInfections and infestations5/866/87
HeadacheNervous system disorders5/866/87
PyrexiaGeneral disorders4/862/87
Upper respiratory tract infectionInfections and infestations2/864/87
CoughRespiratory, thoracic and mediastinal disorders2/864/87
Viral infectionInfections and infestations3/861/87
Ear infectionInfections and infestations2/863/87
Body temperature increasedInvestigations1/863/87

Baseline characteristics

The safety analysis set included all participants who received at least 1 dose of study intervention. The participants were analyzed according to the intervention they actually received.

Age, Continuous
Age, Continuous(Years)Daily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily GenotropinTotal
Mean10.8 ± 3.410.7 ± 3.710.7 ± 3.5
Sex: Female, Male
Sex: Female, Male(Participants)Daily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily GenotropinTotal
Female9615
Male343872
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Daily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily GenotropinTotal
Hispanic or Latino325
Not Hispanic or Latino394281
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Daily Genotropin Then Weekly SomatrogonWeekly Somatrogon Then Daily GenotropinTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American314
White394281
More than one race000
Unknown or Not Reported101
08

Study locations

32 sites
  • Center of Excellence in Diabetes and Endocrinology
    Sacramento, California 95821, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Rocky Mountain Pediatric Endocrinology
    Centennial, Colorado 80112, United States
  • Pediatric Endocrine Associates, PC
    Greenwood Village, Colorado 80111, United States
  • Nemours Children's Health System
    Jacksonville, Florida 32207, United States
  • Nemours Children's Specialty Care
    Jacksonville, Florida 32207, United States
  • Nemours Biomedical Research
    Orlando, Florida 32827, United States
  • Nemours Children's Hospital
    Orlando, Florida 32827, United States
  • Nemours Children's Clinic
    Pensacola, Florida 32514, United States
  • Shriners Hospitals for Children
    Tampa, Florida 33612, United States
  • Emory Children's Center
    Atlanta, Georgia 30322, United States
  • IU Health Pharmacy
    Indianapolis, Indiana 46202, United States
  • Riley Hospital for Children
    Indianapolis, Indiana 46202, United States
  • Children's Mercy Hospital and Clinics
    Kansas City, Missouri 64111, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Children's Hospital of Pittsburgh of UPMC
    Pittsburgh, Pennsylvania 15224, United States
  • MultiCare Health System - Mary Bridge Children's Health Center
    Tacoma, Washington 98405, United States
  • MultiCare Institute for Research & Innovation
    Tacoma, Washington 98405, United States
  • First Pediatric Clinic UMHAT "St. Marina" EAD
    Varna, 9010, Bulgaria
  • Fakultni nemocnice Brno, Pediatricka Klinika
    Brno, 61300, Czechia
  • Nemocnicni lekarna FN Brno
    Brno, 61300, Czechia
  • Fakultni nemocnice v Motole, Pediatricka klinika 2.LF UK a FN Motol
    Praha 5, 150 06, Czechia
  • Nemocnicni lekarna FN Motol
    Praha 5, 150 06, Czechia
  • Nemocnicna Lekaren Nudch
    Bratislava, 833 40, Slovakia
  • Národný ústav detských chorôb, Detská klinika
    Bratislava, 833 40, Slovakia
  • Detská fakultná nemocnica Košice Klinika detí a dorastu LF UPJŠ a DFN
    Kosice, 040 11, Slovakia
  • Nemocnica lekaren DFN Kosice, Klinika deti a dorastu
    Kosice, 040 11, Slovakia
  • St. Georges University Hospitals NHS Foundation Trust
    London, SW17 0QT, United Kingdom
  • St. Georges University Hospital NHS Foundation Trust
    London, SW17 0RE, United Kingdom
  • The Institute of Child Health, University College London
    London, WC1N 1EH, United Kingdom
  • Great Ormond Street Hospital
    London, WC1N 3JH, United Kingdom
  • NIHR Clinical Research Facility, Great Ormond Street Hospital for Children NHS Trust
    London, WC1N 3JH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Aug 2020, 18 months.

Results were first posted in Oct 2021, 1 year 1 month after primary completion.

Of 19 phase 3 interventional studies under Dwarfism, Pituitary, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2018
First posted
Feb 6, 2019
StartActual
Feb 7, 2019
Primary completionActual
Aug 28, 2020
CompletionActual
Aug 28, 2020
Results first posted
Oct 14, 2021
Last update
Oct 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03831880
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 6, 2019
Start date
Feb 7, 2019
Primary completion
Aug 28, 2020
Completion
Aug 28, 2020
Results posted
Oct 14, 2021
Last update
Oct 14, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Human Growth Hormone · Somatrogon

Start the discussion